Abstract | High-throughput DNA sequencing has revolutionized the study of cancer genomics with numerous discoveries that are relevant to cancer diagnosis and treatment. The latest sequencing and analysis methods have successfully identified somatic alterations, including single-nucleotide variants, insertions and deletions, copy-number aberrations, structural variants and gene fusions. Additional computational techniques have proved useful for defining the mutations, genes and molecular networks that drive diverse cancer phenotypes and that determine clonal architectures in tumour samples. Collectively, these tools have advanced the study of genomic, transcriptomic and epigenomic alterations in cancer, and their association to clinical properties. Here, we review cancer genomics software and the insights that have been gained from their application. 
Frederick Sanger and colleagues jump-started the nascent field of genomics in 1977 with their development of chain termination DNA sequencing 1, 2 . It founded a series of commercial instruments that helped to produce numerous early milestones, including the sequencing of the first human genome 3 . Work was slow and expensive (the Human Genome Project costed about 1 billion US dollars), and enormous gains in economy and speed would be needed before the approach could be widely applied. Next-generation sequencing -the generic name for a range of advanced techniques -includes pyrosequencing, sequencing-by-ligation and sequencing-by-synthesis. State-of-the-art instruments now process a whole genome in less than a week and for nominally less than ten thousand dollars. Many thousands of genomes and exomes have since been sequenced, and such data have had an enormous impact on cancer research. Cancer genomics is a now-recognized subspecialty that grew out of the application of sequencing in cancer research. It broadly seeks to characterize germline variants and somatic mutations in individual patients, to use such data from cohorts to identify driver mutations, germline predispositions and environmental factors that are related to cancer and, ultimately, to synthesize such information into mechanistic theories and to develop information systems to assist clinicians with diagnosis and treatment decisions.
Besides advances in sequencing instruments, cancer genomics owes a considerable 'debt' to computing hardware and software. Biology has been steadily absorbing the knowledge, techniques and analytical culture of computer science and mathematics, and this has enabled the development of workhorse algorithms for sequence alignment, the detection of somatic mutational events and the identification of significantly mutated genes (SMGs). However, expansion in computing power is no longer pacing increases in instrument throughput, which means that the bottleneck is quickly shifting from data generation to data analysis. Taken with newer highthroughput streams such as RNA and protein sequences, as well as with the incorporation of data intensive diagnostics such as imaging, the scope of the problem is clear. As the gap between the investigator's abilities to generate and analyse data grows, genomics will increasingly experience the kinds of 'big data pains' that are already familiar to other data-centric disciplines such as particle physics. One of the foremost issues will be to integrate these many data types to open new frontiers in research.
The field of cancer genomics has advanced substantially since the first cancer genome was sequenced merely five years ago 4 . Whole-genome sequencing (WGS), exome sequencing and RNA sequencing (RNA-seq) are now routinely used in cancer studies, and tools continue to be deployed for even more sophisticated analyses, for example, for combining WGS and RNA-seq data to detect fusion genes and for interpreting cancer genomes across several patients to discover driver mutations and pathways. Such analyses have led to discovery of new cancer genes and cancer-causing mutations, and they have shown how environmental exposure leads to characteristic mutational spectra. In this Review, we discuss 
Sequencing-by-ligation
A sequencing method based on the mismatch sensitivity of DNA ligase to detect nucleotides.
Sequencing-by-synthesis
A sequencing method that uses sequential polymerization of nucleotides to a template, in which each incorporation is inferred by an imaging process, usually from a fluorescent dye attached to the added nucleotide.
Driver mutations
Somatic mutations that have causal roles in initiation, progression, metastasis or recurrence of cancer.
Significantly mutated genes (SMGs) . Genes with rates of somatic mutations that are higher than the random background rates, which suggests a role in tumour initiation or progression.
state-of-the-art data generation in cancer genomics, current methods for pre-processing the raw data to detect signals, and higher-level analyses of individuals (Level I) and cohorts (Level II) for biomedical research and clinical applications (FIG. 1) . Moreover, we remark on some important open problems and speculate on the future of this research field in the next several years.
Sequencing strategies
Sequencing is a broad term for interrogating a range of molecular entities, including an entire static genome (WGS) 5 , strictly the coding genomic regions (exome sequencing) 6 , the transcriptome (RNA-seq) 7 as a 'snapshot' of the mRNAs present at a given time and tissue location, genomic methylation patterns 8 and peptides (protein sequence). As coding genomic sequences constitute only 1-2% of the genome, the cost for exome sequencing is still appreciably lower than for WGS. However, such differences are gradually becoming less important, as technological improvements continue to decrease overall sequencing costs. Despite its higher cost, WGS might be preferable, as it provides information on structural and non-coding variants, which cannot be captured from exome-only data. WGS data are therefore considered to be the unbiased 'gold standard' (REF. 9) , and the field is likely to shift increasingly towards this form of data.
Traditional sequencing analyses.
For an individual patient with cancer, the immediate goal of any sequencing procedure is to identify germline and somatic variants that are linked to the cancer phenotype. Typically, tumour and normal tissue samples are collected, sequenced, aligned to the reference genome and compared against Figure 1 | Sample procurement, sequencing and analysis roadmap. a | Most cancer genomic investigations sequence the genome of a tumour sample from a primary or metastatic lesion, starting with a nonspecific 'global' sample pooled from a biopsy specimen or resection. As the spatial distribution of any resident subclones is not known a priori, it will become increasingly common to sequence specific regions from a tumour section separately. In the limit, single-cell sequencing can also be carried out on nuclei sorted by flow cytometry to assess cellular diversity. b | Tumour and adjacent healthy tissue samples are sequenced using high-throughput methods, such as whole-genome sequencing (WGS), exome sequencing and RNA sequencing (RNA-seq). After alignment, a range of detection tools identifies both small alterations (such as single-nucleotide variants (SNVs), and insertions and deletions (indels)) and large alterations (such as copy-number aberrations (CNAs), structural variants (SVs) and gene fusions), which are then annotated and analysed individually (Level I) -for example, for likely functional implications -and collectively (Level II) each other to identify genomic differences (FIG. 1) . Many of the reported differences represent bona fide somatic aberrations, but such findings should ideally be validated by more comprehensive data from an independent platform. There are many different kinds and sizes of mutations, for example, single-nucleotide variants (SNVs), copy-number aberrations (CNAs), and small insertions and deletions (indels), each of which is detected through specific algorithms. In practice, detection of all germline and somatic aberrations is a formidable challenge owing to limitations in current analysis algorithms (see below), as well as to the quantity and quality of sequence data. Important events may be missed when sequence coverage is too low, or when repetitive or complex genomic regions complicate the alignment and assembly of sequence variants. Sequence coverage theory has co-evolved with sequencing technologies and predicts that the amount of data must increase as we seek to identify increasingly subtle genomic signals
Subclonal analyses. As sequencing costs continue to decrease, researchers are able to sequence tumour samples to greater sequencing depths, which enables new analyses. For example, cancer progression has long been known to be a fundamentally clonal process 10 , and sequence coverage is now becoming sufficiently large to permit detection of the low-prevalence events that are routinely associated with tumour subclones 11 . In recent years, multisite and/or multistage sequencing and tumour sectioning experiments have begun to identify founding clones and subclones that contribute to cancer progression [11] [12] [13] [14] (FIG. 1a) . Mutations in subclones are typically mapped at low variant allele fraction (VAF) and often occur against a background of impure tumour and/or normal sample collection. Their identification is extremely difficult, and this observation is partially quantified by the sequence coverage theory
Single-cell sequencing. Pioneering work on assessing CNAs in multiple tumour subpopulations 13 was followed by single-cell sequencing 15 using whole-genome amplification (WGA) of DNA extracted from nuclei that were sorted by flow cytometry (FIG. 1a) . Single-cell DNA and RNA sequencing are now routinely used for revealing cellular diversities within a tumour. However, there are still important challenges, such as amplification biases from degenerate oligonucleotide-primed WGA 15 and multiple displacement amplification techniques 16, 17 . These biases lead to uneven coverage and consequent difficulties for identifying somatic alterations, including SNVs, CNAs and structural aberrations. Sensitivity is most affected by allele dropout owing to the preferential amplification of one of two alleles, and dropout rates of 8-40% 16, 18 have been reported. Large CNAs can still be examined with low genome coverage (for example, 5-6%) by computing read counts in variable-sized bins 19 , whereas unequal coverage renders analyses of smaller CNAs and structural variants extremely difficult. Despite these challenges, recent advances, such as assembly algorithms that handle uneven sequence coverage 20 , point to widespread application of single-cell sequencing in the future.
Dissecting genomic changes in cancer Somatic aberrations contain crucial information about the mechanisms of tumour development, progression, metastasis and relapse. In addition, subsets of these aberrations that are 'clinically actionable' have important implications in inferring prognosis and guiding decisions about treatment. The need for accurately identifying these events has spawned a wide collection of algorithms and software (FIG. 1b) . Most tools use either a composite statistical score or a formal probability test, although there also remain simple heuristic thresholds. TABLE 1 lists some of the more widely used algorithms for detection of SNVs, indels, structural variants and gene fusions, as well as for additional analyses, including identification of driver genes.
Box 1 | Coverage considerations
Early sequencing projects were based on the Lander-Waterman theory 156 for haploid coverage, which recommended a redundancy factor (ρ) of ~10X. Disregarding biases, this implies that loci are spanned by an average of 10 sequence reads and that >99.99% of the genome is represented by the data 156 . However, for medical applications, both alleles must be reliably identified. The identification of a single-nucleotide variant (SNV) requires its observation in multiple reads (usually at least three), and the accrual of these reads is determined by the random dynamics of sampling and coverage quantified in the ideal case (that is, pure samples, perfect data and no sequence bias). If the minimum condition is ≥3 spanning reads per allele, a figure of ρ ≈ 30X is then required to attain approximately the same 99.99% standard . This has been the de facto redundancy for cancer sequencing projects with respect to detecting SNVs, although it does not apply to other types of events. For example, the presence of insertions and deletions (indels) is suggested whenever the reference-aligned average length of spanning fragments is significantly different from the average fragment length of the originating library
52
. It is tricky to apply this principle 49, 158 because a genuine event has to be distinguished from cases in which predominantly shorter or longer fragments were sampled merely by chance. At 30X, the size range of insertions for which indels can be detected with low type I error is narrow, which suggests that more data are needed 159 . There are even greater data requirements if somatic mutational events within subclones of a tumour are to be identified. For a subclone with a mass that is a fraction μ of that of the total tumour, the probability of at least 3 reads reporting a heterozygous variant is
/2), where R = μρ/2. In a 5% mass subclone, the remarkable figure of 340X data is required if 99% of subclonal variants have to meet the detection conditions (see the figure) . Smaller subclones require even more data and readily reach 500X in certain instances. The biomedical relevance of subclones and the growing throughput of instruments mean that the amount of data generated for cancer genomic projects will continue to increase. Nature Reviews | Genetics 
Type I errors
Errors made when effects are declared when none actually exists, which lead to false positives.
Type II errors
Errors made when actual effects are overlooked, which lead to false negatives.
Paired-end mapping
Coordinated mapping of both sequenced ends of a fragment to a reference genome, in which the approximately known separation between the two ends provides extra information against misalignments.
Gapped alignment
An alignment process in which small gaps are allowed if they support a better fit.
Split read
The phenomenon in which a read spans a deleted site, whereby the read appears to be split in its alignment to a reference.
De novo assembly
Reconstruction of a genomic target by assessing consensus sequence from alignments of overlapping reads and clones.
Precision
The fraction of the total number of called events that are true.
Despite impressive progress, the variant-calling problem remains unresolved, and we believe that there is yet appreciable room for improvement in algorithm sophistication and accuracy. Numerous ad hoc procedures have been developed to improve performance of existing tools. For example, it is known empirically that a candidate event called by several independent algorithms is less likely to be a false positive than if it were called by any single algorithm alone. Consequently, multicaller strategies, in which several detectors 21 are used, have now become more common. Of course, sensitivity can suffer, as the overall discovery power now depends jointly on the power of the individual tools. Although preliminary work 22 has been reported, there are no conclusive studies that recommend specific combinations of such tools for optimally balancing type I errors versus type II errors, perhaps because such studies require a large amount of computation. As there are more than two dozen published SNV-specific detectors alone, a 3-caller approach would need to evaluate >2,000 possible combinations. Knowledge of the best algorithm combinations for detecting various types of somatic mutational events would be valuable to the community.
SNV detection.
SNVs are the most frequent alterations in cancer genomes. Numerous SNV detection algorithms have been developed, including the Genome Analysis Toolkit (GATK) 23 The first three handle both germline and somatic variants, whereas the others were designed for calling somatic mutations using tumour and matched normal genomic sequences. Although heterozygous VAFs of 50% are expected in germline samples, this number often does not hold for somatic sites in tumours mainly owing to contamination by normal tissues and/or tumour heterogeneity. Algorithm development is now focusing on handling somatic mutations over a wide range of VAFs. One example is the Bassovac algorithm that considers dependence on bidirectional impurities and tumour subclonal structures (that is, heterogeneity) at the read level, which is a necessary condition for avoiding ad hoc modelling and heuristics. Preliminary findings show improved performance, especially for events that have low VAFs.
Indel detection. Indel detection is still challenging, mainly owing both to their lower frequencies than those of SNVs 32, 33 and to mapping difficulties 34 . Although existing alignment tools are adequate for mapping reads that contain SNVs, they lack the necessary accuracy and sensitivity for reads that overlap with indels or structural variants. Most tools by default allow only two mismatches and no gaps in 'seeded' regions (that is, in the first 28 bp in a read), which prohibits indel-containing reads from aligning to the reference. Paired-end mapping is tremendously helpful in identifying larger indels when the ends occur in flanking regions, which enables inference of altered intervening sequences
. Gapped alignment, split read and de novo assembly are common approaches for detecting indels. VarScan 25 and GATK Unified Genotyper 23 are based on heuristics for indel calling using raw statistics such as coverage, number of indel-supporting reads, read mapping qualities and mismatch counts.
Many existing tools 23, 25, 26 work well for detecting short indels (<5-8 bp) but suffer from lack of precision (that is, positive predictive value) (FIG. 1b ; TABLE 1 ). Furthermore, they often cannot detect medium-size indels, including some known 'druggable' and/or prognostic events, using short-read data. For example, internal tandem duplications of the fms-related tyrosine kinase 3 (FLT3) gene, which are present in 20% of patients with acute myeloid leukaemia who are associated with poor prognosis 35 , are often overlooked because of mapping difficulties 36 . Finally, detection around low-complexity regions (such as homopolymers) is particularly challenging. SAMtools 26 finds short indels by correcting for the effect of flanking tandem repeats and usually produces a large number of indel calls in the process. Dindel (detection of indels) 37 applies a Bayesian approach for calling small indels (<50 bp) by realigning previously mapped reads to generate candidate haplotypes and computing a posterior probability for each haplotype for downstream analyses. Conversely, Pindel 38 takes a pattern growth approach borrowed from protein data analyses 39 to detect indel breakpoints using both split reads and paired-end reads. A similar approach is used in DELLY to detect structural variants 40 . Pindel achieves high precision, and its sensitivity has been improved by allowing mismatches during the pattern matching process. The recent application of Burrows Wheeler aligner (BWA)-MEM 41 alignment allows better mapping around long indels and structural variants. Moreover, local de novo assembly or multiple alignments around candidate indel sites (for example, using GATK haplotype caller and targeted iterative graph routing assembler (TIGRA) local assembly 42 ) reduce the number of false-positive indels. This process is used in many pipelines for indel detection.
CNA and structural variant detection. Unlike SNVs or small indels, CNAs typically affect more than one gene. Traditionally, single-nucleotide polymorphism (SNP) genotyping data have been used for studying CNAs in cancer, and the CNA landscape across multiple cancer types has been reported 43, 44 . Accurate inference of copy number from sequence data requires normalization procedures that consider certain biases inherent to short-read sequencing methods (such as GC content and library biases). Approaches have been implemented for both GC-based coverage normalization and mapping bias 45, 46 . Genomic identification of significant targets in cancer (GISTIC) 47 and correlation matrix diagonal segmentation (CMDS) 48 have been developed for the identification of recurrent CNAs.
Structural changes in chromosomes -such as chromosome deletions, insertions, inversions and translocations -represent another major source of somatic variation in cancer genomes. Most known cancer genes are affected to varying degrees by rearrangements that result in either a fusion transcript or transcriptional dysregulation. Cytogenetics, spectral karyotyping and fluorescent in situ hybridization have previously identified large chromosomal events in several cancer types (such as the breakpoint cluster region (BCR)-ABL1 translocation in chronic myeloid leukaemia). Early end-sequencing profiling of bacterial artificial chromosome and Fosmid libraries revealed complex chromosomal architectures in several human cancers [49] [50] [51] [52] [53] . In recent years, high-throughput WGS of tumour samples has further improved the ability to detect somatic rearrangements and to characterize their breakpoints with base-pair resolution. The identification and analysis of read pairs that do not align as anticipated enable the detection of a wide range of structural alterations, including deletions, tandem or inverted duplications, inversions, insertions and translocations in many cancer genomes. BreakDancer 54 , CREST (clipping reveals structure) 55 , VariationHunter 56 , geometric analysis of structural variants (GASV)-Pro 57, 58 and Genome STRucture In Populations (Genome STRiP) 59 are among the pioneering and most popular algorithms for such analyses (FIG. 1b; TABLE 1 ). BreakDancer carries out de novo pre diction of deletions, insertions, inversions and translocations on the basis of a Poisson model for the number of supporting reads, size of anchoring regions and overall genome coverage. CREST uses the soft clipping carried out by the BWA software package and similar aligners to predict diverse structural events. GASV analyses structural variants and improves breakpoint identification using a geometric bounding algorithm; GASV-Pro extends this approach by incorporating read depth to further improve variant calls. Genome STRiP characterizes genome deletion polymorphism using population-level concepts to re-interpret the technical features of sequence data that often reflect structural variation. Although these approaches are fairly sensitive, the paired-end strategy tends to yield many false positives owing to sequencing errors or read misalignments (especially those within repetitive sequences). Similar to indel detection, local assembly is also widely considered to be a reliable supplement for reducing false positives and for improving breakpoint resolution of structural variants.
Gene fusion detection. The expression of gene fusions that arise through genomic structural rearrangements is a major mechanism for tumour initiation and progression. BCR-ABL1 in chronic myeloid leukaemia 60 , PML-RARA (retinoic acid receptor alpha) in acute promyelocytic leukaemia 61, 62 and TMPRSS2 (transmembrane protease serine 2)-ERG in prostate cancer 63 are among the most recurrent functional gene fusions that have so far been identified. Recently, algorithms such as TopHat-fusion 64 , deFuse 65 , MapSplice 66 , ChimeraScan 67 and BreakFusion 68 have been developed to detect fusions from RNA-seq data (FIG. 1b; TABLE 1 ). These tools are algorithmically similar to their genomic counterparts, although they focus primarily on mapping and ascertaining novel sequence junctions that are produced by mRNA splicing, and depend more on genome annotations. It is increasingly clear that gene fusions can arise both from simple translocations that involve only two distal genomic loci 60 and from complex rearrangements that consist of several distal loci 69, 70 . Therefore, concurrent detection of gene fusions and the originating rearrangements using systematic approaches can improve the accuracy of predictions and help to delineate the underlying mechanistic aspects of gene fusion products. Two tools -Comrad 71 and nFuse 72 -were developed to address this challenge. Both of these align raw WGS and RNA-seq reads while simultaneously corroborating fusions and genomic breakpoint discovery. Comrad, which was the first to be developed, only maps a single fusion breakpoint to a single genomic breakpoint through the application of a set of ad hoc rules. nFuse is an extension of Comrad and maps fusion breakpoints to complex structural rearrangements using a graphtheoretic approach. The advantage of these two methods is that they account for ambiguous read alignment and therefore minimize errors caused by misalignments. We have recently developed BreakTrans 73 , which jointly analyses WGS and RNA-seq data to test hypotheses produced by other tools (such as TopHat-fusion, MapSplice, BreakDancer and CREST) to further delineate the mechanistic components of gene fusions. Variants of various types and sizes described above require sophisticated tools for annotating and interpreting their effects.
Driver mutations and pathways
Following the identification of somatic alterations, the next challenge is to distinguish driver mutations from passenger mutations. Because of the ease of assessing the recurrence and frequency of somatic mutations relative Background mutation rate (BMR) . The rate at which spontaneous mutations occur as a result of uncorrected copying errors.
to the efforts necessary to validate their function, many computational and statistical techniques have been introduced to predict driver mutations and genes. These techniques can be divided into three general categories on the basis of their underlying strategies: variant effect prediction; recurrence and frequency assessment; and pathway or network analysis.
Annotations and functional predictions. In recent years, various genome annotation databases have been consolidated into centralized sources with great improvement in quality and comprehensiveness. Ensembl and the University of California Santa Cruz have emerged as leading repositories of genes and transcripts from GENCODE and RefSeq; regulatory elements identified by the Encyclopedia of DNA Elements (ENCODE), TransFac and RegulomeDB; non-coding RNAs from NONCODE, BodyMap and miRBase; and protein annotations from Pfam and Interpro. There has been a concurrent emergence of software that takes advantage of these resources to annotate variants in coding and noncoding regions genome wide. ANNOVAR 74 89 have been developed to predict effects that are related to protein aggregation, protein stability and alterations of residues targeted by post-translational modification.
Significantly mutated genes. The most widely used approach to distinguish driver mutations from passenger mutations is to identify the mutations that occur more often than expected by chance. This approach is generally applicable across cancer types and is especially well suited for mutagenic phenomena that are associated with specific kinds of cancers, for example, viral disruption in ovarian and cervical cancers, smoking-and tobaccoinduced mutations in lung and oral cancers, and ultraviolet (UVA, UVB or UVC) radiation-induced mutations in melanoma (FIG. 2; BOX 2) . In the simplest case, one assumes that the background mutation rate (BMR) of a gene is known and evaluates the probability of passenger mutations in a given number of samples using a statistical test 90, 91 . The primary difficulty is obtaining good BMR estimates, as inaccuracies can lead to incorrect association of a gene with cancer. Many factors are known to affect the BMR of a gene (FIG. 2) , including covariates, variation among samples and errors in upstream analyses. Covariates include differences in gene length, expression level and replication timing. Mutation frequencies can differ not only across patients with the same cancer type but also as a result of diverse mutational spectra across cancer types that are possibly associated with environmental factors and viral signatures. Finally, incorrect or biased annotation of mutations can markedly contribute to potential false positives in cancer gene analyses. For example, multiple open reading frames in genes such as tenascin N (TTN) or incomplete description of pseudogenes in olfactory receptor loci can lead to incorrect assignment and annotation of mutations that result in false predictions. Inadequate sequence coverage of a gene exacerbates these problems. Software that accounts for these contingencies includes MuSiC 92 and MutSig 93 , which have been extensively used in many large-scale cancer studies [94] [95] [96] [97] [98] . Both tools integrate heterogeneities using convolution to obtain probability tails. There are additional covariates that are not taken into account, and it is likely that frequency methods will continue to be developed.
Another approach that has been used to distinguish between driver mutations and passenger mutations is to examine whether mutations cluster at specific residues of the protein sequence. The '20/20 rule' (REF. 99 ) advises that a gene should be classified as an oncogene if at least 20% of its missense mutations (or identical in-frame indels) are located at a particular residue. Conversely, a gene can be classified as a tumour suppressor if at least 20% of the mutations are inactivating (that is, nonsense, frameshift, splice site or stop codon read-through mutations). This heuristic is applicable to many well-known cancer genes but is also arbitrary in the use of a fixed 20% threshold. It is now being supplemented by algorithms that assess patterns of mutational signatures 100 and clustering of mutations in protein sequence 101 or three-dimensional protein structure 102 using more rigorous statistical scores. Recent methods have shown that combining different signals of positive selection holds great potential for finding reliable lists of driver genes 103 .
Pathway and network analyses. An enhanced understanding of somatic mutations can be gained by examining collections of mutations in signalling, regulatory or metabolic pathways (FIG. 3) . It is well established that functional somatic mutations deregulate these pathways, and researchers have used a range of approaches to assess the clustering of mutations in known pathways and interaction networks. These approaches can be divided into two classes: those that analyse known (that is, curated) pathways, which are represented as gene sets, and those that analyse interaction networks to implicitly build pathways de novo.
A straightforward approach to evaluate combinations of mutated genes is to examine the overlap between lists of mutated genes and pre-defined gene sets that have known biological function. This technique has been used for more than a decade in gene expression analyses to evaluate lists of differentially expressed genes. Databases that record functional annotations of human genes include the Kyoto Encyclopedia of Genes and Genomes (KEGG) 104 , Gene Ontology (GO) 105 and the Molecular Signatures Database (MSigDB) 106 . For example, suppose we have a list of mutated genes (M), and we aim to see whether this list contains genes that are involved in regulation of the cell cycle. Using the KEGG database, we find a list of more than two dozen cell cycle genes (L). There are two statistical tests that can be used to test whether M and L have significant overlap. First, if M is ranked (for example, using one of the mutation significance scores described above), then gene-set enrichment analysis (GSEA) 106 can be used to determine whether the genes in L are near the top of the ranked list (M) 107 . Second, if M is unranked, then the overlap between M and L can be assessed using a hypergeometric test 108 . More recently, specialized tests for SMG sets have been introduced. The most direct approach is to adapt one of the SMG tests (for example, MuSiC and MutSig) described above. More sophisticated approaches such as PathScan 109 and a recently developed patient-oriented method 110 allow varying BMRs across annotated genes.
Examination of gene sets overcomes some of the limitations of single-gene tests of recurrence; in particular, these tests can assign significance to rarely mutated genes when they appear in the same pathway. However, these tests also have some limitations. Human gene annotations and pathway databases remain incomplete, and there is extensive crosstalk between pathways, which implies that decisions regarding the genes that form the boundary of a pathway are arbitrary to some extent. The crosstalk is represented in gene-set and pathway databases by the presence of multiple overlapping gene sets, thus complicating the interpretation of reported enrichments. Finally, signalling and regulatory pathways have a rich topology of activating and inhibitory interactions, and this information is not represented in the list of genes or proteins that are members of the pathway.
To overcome these limitations, a second approach for analysing combinations of mutations is to use biological interaction networks. Various genome-scale proteinprotein interaction networks have been constructed in the past few years. For example, the human protein Nature Reviews | Genetics reference database (HPRD) 111 , KEGG 104 and Reactome 112 summarize experimentally validated protein-protein interactions, whereas other databases -such as BioGRID 113 , search tool for the retrieval of interacting genes/proteins (STRING) 114 , high-quality interactomes (HINT) 115 and iRefIndex 116 -integrate interaction information from multiple data sources, including protein-protein interactions derived from high-throughput experiments. The resulting protein-protein interaction networks contain >10,000 proteins and >50,000 interactions. More recently, protein-DNA interactions from the ENCODE project 117 have been integrated into these networks 118 . Interaction networks have been used in place of gene sets to determine combinations of mutations that should be further evaluated. However, most biological networks have a non-uniform topology that is characterized by the presence of hubs or nodes. This topology must be taken into account when defining mutated subnetworks. HotNet 119 is a method to find subnetworks of a large interaction network that are mutated in more samples than expected by chance. It uses a heat diffusion model to simultaneously encode both the topology of the network and the significance of the observed frequencies of each mutated gene. Genes (or their corresponding proteins) are assigned an initial heat according to their mutation frequency or significance. This heat then diffuses over the edges of a network. Thus, significantly mutated subnetworks correspond to hot spots in the network. The number and size of such subnetworks are then tested for significance. HotNet has been used to determine subnetworks in several cancer types that were analysed in the context of The Cancer Genome Atlas (TCGA) 95, 97, 120 and has, for example, implicated mutations in the Notch signalling pathway in ovarian carcinoma 95 .
Recently, network-based stratification (NBS) 121 used a similar heat diffusion model to define subtypes of tumour samples by clustering smoothed mutation profiles. Mutual Exclusivity Modules in cancer (MEMo) 122 is another approach to find mutated subnetworks using the observation that driver mutations in interacting proteins are often mutually exclusive across patients 123, 124 (see below). MEMo first defines modules of highly connected nodes in the network and then assesses whether these network modules show mutually exclusive mutations. It has been used in several cancer types reported in TCGA 96, 120 . Another approach used in TCGA studies 120 is Tied Diffusion Through Interacting Events (TieDIE) 125 , which uses a network diffusion approach to connect genetic abnormalities (for example, somatic mutations) to transcriptional changes. Many other methods have been introduced to examine networks using gene expression 126 , which are not discussed in detail here. A third approach that has been used to analyse combinations of mutations is the identification of mutually exclusive sets of mutations. For example, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutations and PTEN (phosphatase and tensin homologue) deletion are mutually exclusive in breast cancer 127 . Inverting this idea, one might find combinations of driver mutations by identifying mutually exclusive sets of mutations. MEMo 122 uses this idea to examine genes with known interactions, as noted above. Alternatively, one may attempt to discover sets of mutually exclusive genes de novo without prior restrictions on the sets of genes. This idea forms the basis of the De Novo Driver Exclusivity (Dendrix) algorithm 128 , as well as the Multi-Dendrix 129 and RME (recurrent and mutually exclusive) 130 algorithms. The Dendrix algorithm was used in the acute myeloid leukaemia project of TCGA 97 and in a Pan-Cancer TCGA analysis of 12 cancer types 131 .
Box 2 | Detection of environmental impact on cancer genomes
Healthy cells are subject to various external insults that promote mutagenesis, well-known examples of which include cigarette smoke, asbestos and ultraviolet (UV) radiation 160 (see the figure) . Viral infection and age also have roles in mutagenesis 161 . These factors can strongly affect mutation rates across the cancer genome and mutation profiles across cancer types and human populations, which leave characteristic marks on the cancer genome. For example, a comparison of the mutation profiles across 12 common cancer types reveals that lung tumours contain higher proportions of C→A transversions 131 , which are classic signatures of exposure to cigarette smoke. Mutation dynamics are compliant with circumstances 133 , such as by UV exposure in melanomas, mismatch repair defects in colon cancers or viral infections in head and neck tumours 133, 162, 163 . There is also a growing appreciation that viral sequences, both episomal and those integrated into a genome, are more important in cancer than previously thought. Several oncoviruses have already been confirmed, including human papilloma virus, hepatitis B virus, hepatitis C virus, Epstein-Barr virus, human T lymphotropic virus and Merkel cell polyomavirus. However, there are undoubtedly more, and they affect 15-20% of all human cancers 164 . Efforts to systematically characterize viruses in cancer are forthcoming, and screening cancer genomes for viral sequences is likely to become a routine in the future. Despite their propensity for rapid evolution, it is likely that viral sequences will be reasonably detectable owing to their size, for example, using homology-based read alignment and comparison with viral and bacterial databases. PathSeq 165 and rapid identification of non-human sequences (RINS) 166 investigate microbial sequences using the traditional subtraction and intersection approaches, respectively, and research is now underway for developing additional tools for viral discovery.
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Kataegis
The appearance of regions of local hypermutations in a tumour genome.
Currently, a substantial number of SMGs and significantly mutated pathways have been identified both in individual cancer types and across cancer types. The next challenge is to better understand how these genes and pathways interact and function together in individual cancer patients.
Genome integrity and clonal architectures
Accumulation of somatic mutations in a population of tumour cells is the foundation of the clonal theory of cancer, as described by Peter Nowell in 1976 (REF. 10 ). High-throughput sequencing has led to new insights into this process, including the discovery of novel mutational processes and the quantification of the clonal architecture of tumours.
Kataegis, chromothripsis and chromoplexy. One of the more fascinating observations from cancer genome sequencing studies is genomes with extreme numbers and types of mutations. Kataegis is the occurrence of an unusually large number of single-nucleotide mutations clustered in a single locus, and was first reported in breast tumours 132 and other cancer types 133 . It is identified from 'rainfall plots' that illustrate the frequency of single-nucleotide mutations across the genome. Nature Reviews | Genetics Figure 3 | Significantly mutated genes, pathways and networks. Given the mutational status of genes across several patients, one can distinguish driver mutations from passenger mutations using several strategies. Single-gene tests determine whether the observed number of samples having a mutation in the gene is significantly greater than that expected under an appropriate null model. Pathway or gene-set approaches examine whether multiple genes in pre-defined sets -as obtained, for example, from curated databases such as the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO) and the Molecular Signatures Database (MSigDB) -have more mutations than expected. These tests are biased to the prior knowledge of gene sets in these databases, but the numbers of tests are fairly small, and the risks associated with type I error therefore tend to be manageable. Conversely, network approaches rely only on knowledge of known protein-protein or protein-DNA interactions -such as those in the iRefIndex, high-quality interactomes (HINT), BioGRID and search tool for the retrieval of interacting genes/proteins (STRING) databases -in examining combinations of mutations on whole-genome interaction networks, for example, using the heat diffusion process. As these approaches are unbiased, it is possible to infer novel combinations of genes that are relevant to cancer, but larger numbers of hypothesis tests imply that greater care must be taken for multiple-testing correction. Indel, insertion and deletion; SNV, single-nucleotide variant; SV, structural variant.
Pathway databases
MSigDB
Chromothripsis
A catastrophic mutational event that 'shatters' one or more chromosomes, which leads to simultaneous loss and rearrangement of multiple chromosomal segments.
Chromoplexy
A mutational event that results in substantial and complex rearrangements that involve multiple loci, although it is not as severe as chromothripsis and involves less clustering of rearrangement breakpoints.
Clonal evolution
The emergence of novel clones that have improved survival or propagational fitness according to the particular sets of somatic mutations that have accumulated in these clones.
The analogous phenomenon of many genome rearrangement breakpoints clustered at a single locus has long been observed from lower-resolution microarray and cytogenetic studies 134 . However, genome sequencing has revealed a different phenomenon of chromosome shattering -chromothripsis, in which one or more loci undergo a catastrophic event of simultaneous breakage and aberrant repair at multiple breakpoints in a single cell division 70 . Chromothripsis was originally reported in ~2-3% of all cancers but was shown to be particularly common in bone cancers (~25%). It was later reported in paediatric medulloblastomas 135 and was found to be associated with TP53 (which encodes p53) mutations, which indicates a possible mechanism for its appearance 136, 137 . A related process called chromoplexy has now been observed in prostate cancers 138 . It is challenging to distinguish chromothripsis and chromplexy from sequential accumulation of chromosomal rearrangements over several cellular generations. Secondary rearrangements often obscure the signatures of chromothripsis and chromoplexy. The distinction between simultaneous and sequential rearrangement is typically made through simulations 70, 135, 139 , although there have been criticisms of these approaches 140 . In lieu of simulation, putative signatures of chromothripsis have been proposed 141 . Tools that simultaneously analyse several rearrangement breakpoints -such as Paired-end Reconstruction of Genome Organization (PREGO) 142 , nFuse 72 and extensions of Hydra 139 -facilitate the evaluation of these signatures. However, more work is needed to find quantitative measures that distinguish chromothripsis and chromoplexy from sequential accumulation of rearrangements.
Defining clonal architecture in heterogeneous tumours. All genomic alterations discussed above have a role in clonal evolution. Tumour clones are subject to changing selective pressures and to continually accumulating mutations (FIG. 4a) . Genomic alterations collectively reflect this evolutionary history and can be used to reconstruct the subclonal architectures and progression processes that might have led to relapse or metastasis. Such information is important, as clonality has already been implicated in numerous aspects of cancer, including clinical outcome 143 , increased progression and malignancy 144 , and drug resistance 145 . Clonal inference can be challenging. The number and positioning of clones within a tumour are often unknown, and uniform sampling is therefore routinely presumed. Dot plots are often used to obtain visual estimates of clones. For example, each heterozygous SNV can be represented by a dot positioned on orthogonal axes of VAF versus frequency or total reads that represent the variant. As the process is stochastic, such plots cluster into 'dot clouds' (FIG. 4) that are suggestive of clones. If the collective distribution is non-Gaussian (as determined by, for example, the Shapiro-Wilk test or D' Agostino's K-squared test), then multiple clones are presumed to be present. The process of discerning clones individually then encounters more confounders from both experimental contingencies (such as mutual impurities of the tumour and normal samples owing to suffusion or insufficient margin) and biological complications (such as copy-number variations within the tumour genome). There are also subtle statistical factors, including differences in variances of clonal VAF distributions. Specifically, mutations that exist in all tumour cells -namely, those in the most recent common ancestor -have a variance (σ 2 ) that is proportional to unity (σ 2 ∝ 1). Conversely, mutations in a minor subclone with a mass that is a fraction μ of that of the total tumour have σ 2 ∝ μ, which means that its distribution is 'flattened' in this dimension.
Some clonal discovery methods are centred around the mathematical concept of density estimation, a process through which a probability density function (PDF) that best describes the observed data is constructed, for example, using the Parzen-Rosenblatt 146, 147 'window' method. If clusters are sufficiently separated by VAF, then the PDF readily identifies the tumour clones. There are various more recent and sophisticated methods. For example, ABSOLUTE 148 adds an optimally fitted CNA model and a karyotype likelihood model. Conversely, PyClone 149 and a recently developed bioinformatic method 150 identify clones using hierarchical Bayesian clustering 11 . We have developed a method called SciClone (FIG. 4b) that uses Bayesian mixture modelling to examine multiple samples from a patient over time (using initial and relapsing tumour samples) or space (using several biopsy specimens). The Tumor Heterogeneity Analysis (THetA) algorithm 151 accounts for the presence of CNAs, which can confound analyses of VAFs. Similar to the variant calling problem, there has been considerable progress in this area, but substantial improvement is still needed. Not only will better variant detection improve clonal analyses, but additional classes of informationincluding cancer-specific and pan-cancer population data, as well as information from other affected family members -will also help to better define tumour architecture. Finally, direct integration with phylogenetic analysis algorithms may help to arbitrate among certain kinds of multiple alternatives that are currently undecidable 148 .
Conclusion: basic and clinical applications
In the short time since cancer genomics has entered the biomedical scene, it has made numerous fundamental contributions. First, cancer-associated genes and pathways have been identified; second, germline predispositions have been established; third, technologies and algorithms have been improved; fourth, vast data sets have been organized and recorded; and finally, knowledge has been classified into new databases. These accomplishments can be attributed to many projects driven by individual research laboratories, as well as to large-scale collaborative projects carried out by TCGA and the International Cancer Genome Consortium (ICGC) using cutting-edge computational approaches 152, 153 . TCGA has completed nearly 10,000 cancer cases across 20 cancer types, and the ICGC will be sequencing ~25,000 additional genomes across 50 cancer types over the next several years. Furthermore, efforts by the Cancer Cell Line Encyclopedia 154 and Genomics of Drugs Sensitivity in Cancer will help to establish genomic determinants of resistance or sensitivity to drugs. The information and knowledge that will be gained from such projects are expected to have enormous implications both for understanding cancer broadly and for diagnosing and treating tumours at the individual patient level. This will be a tangible step towards personalized medicine.
Widespread clinical application of cancer genome and transcriptome sequencing is a certainty, although the timing remains unclear because of several remaining issues related to both cost and reliability. First, the 'data spectrum' and associated analysis tools are not yet complete. A substantial portion of driver events in cancer are DNA or RNA alterations that affect protein expression, but proteomics has not yet achieved the high-throughput rates and sample census of genomic sequencing. In our view, proteomic data are increasingly important in ascertaining driver genes and pathways, especially in terms of winnowing false positives from the large lists of hypotheses generated by pathway, network and SMG algorithms. However, it is clear that the proteomic gap is starting to close. For example, the Clinical Proteomic Tumor Analysis Consortium Nature Reviews | Genetics (CPTAC) launched by the US National Cancer Institute (NCI) will further many goals, including the characterization of tumour protein inventories, the integration of genomics with proteomics and the development of biomarker assays for high-priority proteins. Associated bioinformatic tools will also be further developed. This will be an increasingly fruitful area of research. The second factor is the reality of cost. The cost of sequencing an individual's genome has decreased by ~5 orders of magnitude from ~1 billion dollars for the first human genome to around $10,000 now. Technological development continues apace, but the overall cost for an entire 'package' (that is, DNA and RNA sequencing, proteomics and companion systematic analysis) is likely to have to decrease by yet another order of magnitude before sequencing can become a routine clinical test. In addition, there will probably be some form of certification process for analysis software. There have even been a few early clinical successes, such as the case of Lukas Wartman, whose comprehensive genome, exome and RNA analysis implicated FLT3 overexpression in his particular form of leukaemia 155 . This analysis led to the decision to administer Sutent, which is a tyrosine kinase inhibitor targeting FLT3 expression that was approved by the US Food and Drug Administration (FDA). This quickly put Wartman's disease into remission that continues now. The next chapter of cancer research will undoubtedly see further pushes towards clinical application and increased involvement of big pharmaceutical companies in developing new therapeutic agents. The cancer landscape will look vastly different from now in a decade, and we will be at the threshold, if not well into the era, of finding cures (or means of conferring long-term remission) for some cancers. Stay tuned.
